Figure 3. Effect of p38 mitogen-activated protein kinases (MAPK) inhibitor on nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) activity. After application of p38 MAPK inhibitor SB203580, the activity of nuclear NF-κB obviously decreased when compared to the ischemia/reperfusion (I/R) control and vehicle groups at 8 h after ischemia/reperfusion (I/R). *Statistically significant compared to the I/R control: p<0.05. n=6 in each group. Nuclear NF-κB p65 activity were given as mean±standard deviation (SD).